BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Isis Pharmaceuticals, Inc. 

Carlsbad Research Center
2292 Faraday Avenue
Carlsbad  California  92008-7208  U.S.A.
Phone: 760-931-9200 Fax: 760-603-4650


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Biotechnology






 Company News
Isis Pharmaceuticals, Inc. (ISIS) Earns $7M for Advancing ISIS-SMN Rx In Children With Spinal Muscular Atrophy 1/14/2015 7:16:36 AM
Isis Pharmaceuticals, Inc. (ISIS) Significantly Improves Upon 2014 Financial Guidance 1/8/2015 9:06:18 AM
Interleukin Genetics Inc. (ILGN) Announces Collaboration With Isis Pharmaceuticals, Inc. (ISIS) For Genetic Testing Services 1/7/2015 12:41:59 PM
Led By Ex-Genzyme Corporation (GENZ) Exec, Isis Pharmaceuticals, Inc. (ISIS)'s Newly Formed Cambridge Subsidiary to Hire 20 1/7/2015 6:36:59 AM
Isis Pharmaceuticals, Inc. (ISIS) Appoints Paula Soteropoulos As President And Chief Executive Officer Of Akcea Therapeutics 1/6/2015 9:25:34 AM
Isis Pharmaceuticals, Inc. (ISIS) Appoints Sarah Boyce As Chief Business Officer 1/6/2015 9:03:36 AM
Isis Pharmaceuticals, Inc. (ISIS) Rockets as Johnson & Johnson (JNJ) Snags Bowel Drug License Option for $835 Million 1/5/2015 6:08:24 AM
Isis Pharmaceuticals, Inc. (ISIS) To Present At The 33rd Annual J.P. Morgan Healthcare Conference 1/2/2015 9:56:37 AM
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 1/2 Study Of ISIS-DMPK Rx In Patients With Myotonic Dystrophy Type 1 12/16/2014 8:08:48 AM
Isis Pharmaceuticals, Inc. (ISIS) Reports Positive Phase 2 Data For ISIS-FXI Rx For The Prevention Of Venous Thrombosis In Patients Undergoing Total Knee Replacement Surgery 12/8/2014 7:57:14 AM
12345678910...